Ideaya Biosciences Has Dosed The First Patient In Phase 1 Trial Evaluating The Combination Of IDE161 In Combination With Merck's Keytruda (Pembrolizumab), In Endometrial Cancer Patients With High Microsatellite Instability And Microsatellite Stable

IDEAYA生物科學已對第一位患者進行給藥，參與評估在高微衛星不穩定性和微衛星穩定性子宮內膜癌患者中使用IDE161與默沙東的Keytruda（帕博利珠單抗）的聯合第1階段試驗。

Benzinga · 2024/12/10 19:06

First patient dosed with combination of IDE161, IDEAYA's investigational, potential first-in-class PARG inhibitor, in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy
The IDEAYA-sponsored Phase 1 clinical trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of IDE161 in combination with KEYTRUDA in patients with MSI-high and MSS endometrial cancer
Selected initial Phase 1/2 expansion dose for IDE161 monotherapy in a priority solid tumor type, based on AE profile and preliminary clinical efficacy observed

首位患者接受了IDE161與默沙東的抗PD-1治療KEYTRUDA（帕博利珠單抗）聯合使用的治療，IDE161是IDEAYA正在研發的潛在首創PARG抑制劑。
IDEAYA贊助的第1期臨床試驗將評估IDE161與KEYTRUDA聯合使用的安全性、耐受性、藥代動力學、藥效學和療效，適用於MSI-high和MSS子宮內膜癌患者。
基於不良事件（AE）特徵和觀察到的初步臨床療效，選擇了IDE161單藥治療在優先實體腫瘤類型中的初步第1/2期擴展劑量。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

風險及免責聲明